The Depression of the Synthesis of Pea Diamine Oxidase Due to Light and the Verification of Its Participation in Growth Processes Using Competitive Inhibitors

Total Page:16

File Type:pdf, Size:1020Kb

The Depression of the Synthesis of Pea Diamine Oxidase Due to Light and the Verification of Its Participation in Growth Processes Using Competitive Inhibitors BIOLOGIA PLA_NTARD2r (PRAHA) 16 (2) : 86--93, 1974 The Depression of the Synthesis of Pea Diamine Oxidase due to Light and the Verification of its Participation in Growth Processes using Competitive inhibitors L. MACHOLi~ and J. Mr~s Departments of Biochemistry and Plant Biology, J. E. Purkynii University, Brno, Czechoslovakia* Received January 2, 1973 Abstraet. The time courses of the synthesis of diamine oxidase in pea plants grown for 14 days either in the light or in the dark are similar with the highest increase in activity occurring in the cotyledons and in the shoots during the first 6 to 8 days. Plants grown in the dark showed a 2- to 3-fold higher enzyme activity than plants grown in the light. Pea diamine oxidase could be in rive efficiently inhibited by substrate analogues 1,4-diamino-2-butanono and 1,5-diamino-3-pentanone. The first compound inhibited proportionally to its concentration the growth of etiolated pea plants, but its instability makes an unoqulvocal interpretation of the results difficult. On the other hand, 1,5-diamino-3-pontanono a stable and more efficient diamino oxldaso inhibitor depressed the growth of pea seedlings only at concentrations as high as 5 m)5 and 10 raM, at which the growth of cress seedlings not containing diamine oxidaso was also strongly depressed. The results obtained indicate that tryptamine oxidation catalyzed by diamine oxidase is not involved in the main metabolic pathway leading from tryptophan to indoleacetate in pea plants. Young pea plants contain high diamine oxidase activity [diamine: oxygen oxidoreduetase (deaminating), EC 1.4.3.6.) which is sometimes simply referred to as amine oxidase. The synthesis of the enzyme starts in the first hours of germination and in normal green plants reaches the highest activity after the first few days (K~TE~ and MA~ 1952, W~.~L~ et al. 1959, 1961). Because amine oxidases are able to oxidize tryptamine, some authors supposed that it could be involved in the formation of indoleacetate (KENTE~ and MA~ 1952, CL)_~KE and MA~ 1957, LAI~TICA~ and MUIR 1967). Ex- periments carried out so far mostly with the inhibitors of hydrazine type lead, however, to contradictory conclusions. REED et al. (1965) and recently KI~URA and TA~AK)~ (1971) found a relation between depressed growth of pea plants and the inhibition of tryptamine oxidation caused by the herbicide B-995 or by monoamine oxidase inhibitors safrazine and nialamide. On the Address: Kotls 2, 611 37 Brno, Czechoslovakia. 86 SYNTHESIS OF PEA D~NE OXIDASE 87 contrary, R. Moss from the Gordon's laboratory (see LARSE~ 1967, page 433) found that indoleacotate production was not changed in the pea stem tissues in which tryptamine oxidase activity was nearly completely inhibited. Aminoguanidine, isonicotinio acid hydrazide, and isopropylhydrazino in- activating diamine oxidase activity in vivo inhibited the germination not only in pea but even in the plant species not containing this enzyme (WEI~LE et al. 1959). In this paper we therefore try to verify if the selective inhibition of diamine oxidase can influence the germination and growth of pea seedlings. Nearly untoxical substrate analogues 1,4-diamino-2-butanone and 1,5-dia- mino-3-pontanone were used as efficient competitive inhibitors of diamine oxidase; they do not affect mitochondrial monoamine oxidase (MAc~oLA~ et al. 1967, MACHOLA~r 1974). Another aim of this paper was to follow the dynamics of the formation of diamine oxidase in pea plants grown either in the light or in the dark. Material and Methods 1,4-diamino-2-butanone dihydrochlerido was prepared after MICltALSK~ etal. (1953) and 1,5-diamino-3-pentanone was synthesized according to a method devised in our laboratory (MAc~OL%_lq 1974). Cultivation of the Plants The experiments were performed with pea seedlings (Pisum sativum L.) cv. Liliput, and, cross plants (Lepidium sativum L.) were used for bioassays. Selected seeds were surface sterilized for 5 rain. with 96% ethanol, rinsed with water, and then soaked for 24 h in distilled water or in inhibiter solution of pH approx. 5.0. The seeds were then transferred onto a layer of granulated polyethylene underlayed with diluted (1 : 4) Richtor's nutrient solution supplemented with microolements in Hoaglan4 A--Z solution. The germination and further cultivation occurred at 23 ~ either in the dark or in continuous light (white and rosy fluorescent tubes 1 : 1, 7 000 lx at the level of the plants) in a chamber with controlled conditions. The volume of the nutrient solution was kept constant by replenishing with distilled water. In the experiments with the inhibitors, groups of 250 seedlings, 3 to 4 days old, were transferred into 1 000 ml flat plastic cultivation vessels containing 500 ml of diluted (1 : 1) nutrient solution either with the inhibitor or without it. Enzyme Extraction and Assays 10 to 22 pea seedlings were carefully washed, and then cotyledons, roots, and shoots wore sepa- rated and weighted. Tostao wore removed from the cotyledons and each plant part was separately homogenized in a mortar with chilled 0.1 M phosphate buffer pH 7.0 and sdica sand (0.2 g of sand per g of plant material). The homogonato was sqeeze4 through a nylon cloth and the remaining pellet was repeatedly extracted with the buffer solution. The filtrate was made up to 50 or 100 ml with the buffer solution and immediately assayed. Protein was determined in the supornatant after centrifuging the homogenate at 10 000 g for 15 rain u~ing a modifigd biurot method with the subtraction of the turbidity after the addition of KCN (SzARI~OWSKX and KLI~'GENBERG 1963). Bovine sorumalbumin was used as standard protein. Diamino oxidaue activity was determined spectrophotomotrically ([-IoI, MSTEDT etal. 1961, M~-C~OLs 1966) at 25 ~ The assay mixture (final volume 5 ml) consisted of 80 mM phosphate buffer pl-I 7.0, 2.5 mM c-aminobenzaldehyde, 20 ~g catalase, 10 mM 1,4-diaminobutano, and 0.5 ml plant extract. One unit (lJ) represents the amount of enzyme catalyzing the formation of one fxmole Al-pyrrolino per rain. Specific activity is expressed in units per mg protein. Results Diamine Oxhlase Level in Pea Plants Grown Either in the Light or in the Dark Diamine oxidase activity was followed in extracts from different parts of plants grown in continuous light or in the dark during the first 14 days. The 88 h. ~[ACHOL~i.N, J. MINAI~ COTYLEDONS SHOOT DAB o4d eed O~ o9e D o<I.- o I ~ I I / DAB oee oed D O11d c DAP o Yd 10d o13d 01 , , ~ ,-- n 2 4 6 8 10 12 2 4 6 8 10 0 2 4 6 8 10 TIME [d] INHIBITOR CONCENTRATION [10 .3 M] Fig. 1. Diamine oxidase activity in pea plants grown in the light and in the dark. Enzyme activity in the cotyledons (~), in the shoots @, and in the roots[~, as expressed per g fresh weight -- A, per plant -- B, and per mg soluble protein -- C. Full symbols: plants grown in the dark, open symbols: plants grown in the light. <1, Diamine oxidase activity in above-ground parts of etiolated plants which were transferred at the time denoted by an arrow into the continuous light. Fig. 2. The inhibition of diamine oxidase in the cotyledons and in the above-ground parts of pea plants grown in the dark by 1,4-diamino-2-butanone (DAB) and 1,5-diamino-3-pentanone (DAP). The inhibitor was applied in the concentrations given in the abscissa either only when soaking the seeds (A), or both to seeds and roots in the diluted (1 : 1) l~ichter's nutrient solution (B, C)o found values were expressed per g fresh weight (Fig. 1A), per plant (Fig. IB), or per mg total soluble protein (Fig. 1C). The synthesis of the enzyme starts soon after the swelling of the seeds and its activity rises sharply in the follow- ing 6 to 8 days, mainly in the cotyledons. This increase in activity is most conspicuous when the activity is expressed per plant. We can see that after an initial sharp increase, the activity changes only slowly in both normal and etiolated plants. When the activity was expressed per fresh weight unit a decrease in diamine oxidase activity was established in the above-ground SYNTHESIS OF PEA DIAMINE OXIDASE 89 parts and in the roots which was obviously connected with the growth of these organs. In the cotyledons which gradually loose their weight, the level of diamine oxidase continuously slowly rises. Specific activity of diamine oxidase progressively rises in the cotyledons but decreases after an initial increase in the above-ground parts during the development of the seedlings. The plants grown in the dark always showed a higher diamine oxidase activity then those grown in the light. At the end of the 14th day of culti- vation approx, a twofold activity was found in the cotyledons and approx. a threefold activity was found in the above-ground parts when expressed per plant (Fig. 1B). When 10 days old etiolated plants were transferred into the light diamine oxidase activity remained at the same level as in control plants kept continuously in the dark (Fig. 1A). This indicates that only the initial phase of the synthesis of diamine oxidase is controlled by the light. The Influence of the Inhibitors The competitive inhibitors of diamine oxidase, 1,4-diamino-2-butanone and 1,5-diamino-3-pentanone, were tested on pea plants grown in water cultures in the dark. 1,4-diamino-2-butanone was applied at the beginning of the experiments to the soaking seeds in 0.625 to 10mM water solutions.
Recommended publications
  • Studies on the Metabolism and Toxicity of Hydrazine in The~Rat~
    STUDIES ON THE METABOLISM AND TOXICITY OF HYDRAZINE IN THE~RAT~ Andrew Michael Jenner, B.Sc. Submitted to the University of London for the examination of the degree for Doctor of Philosophy, 1992 Toxicology Department The School of Pharmacy Brunswick Square London ProQuest Number: U068521 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest U068521 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENTS I would like to express my sincere appreciation to my supervisor Dr. John Timbrell for his invaluable advice, guidance and support. Many people have assisted the progress of my studies in a wide variety of ways, including everyone who has worked alongside me in the Toxicology Unit, both past and present. Particular thanks go to Simon (ET) for his critical eye and mutual, down to earth Yorkshire mentality and also to Cathy for her heartening encouragement. I would also like to thank Dr. Alan Boobis for his assistance in obtaining human liver samples and to the USAF for funding this project. Finally I would like to recognise Jacqui for her designs, Maria for her typing, Justina for her continuous care and support and to my mum and dad for their understanding and my much appreciated conveyance through life.
    [Show full text]
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • Les Femmes Peuvent Prendre Du Viagra * Achat De Viagra En
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Les femmes peuvent prendre du viagra Tags: cialis ou viagra acheter vrai ou faux viagra risques avec viagra acheter du viagra sans ordonnance en suisse danger du faux viagra comment bien prendre viagra le prix du viagra en pharmacie au maroc les effets indesirable du viagra que ce que viagra de gaulle contre le viagra achat viagra internet doctissimo commande viagra belgique peut on avoir du viagra en pharmacie sans ordonnance comment prendre sildenafil pfizer nitrates and viagra interaction ordonnance ou pas pour viagra notice demballage viagran quels sont les effets du viagra quelle quantité de viagra prendre peut on acheter viagra en pharmacie sans ordonnance comment avoir le viagra site sur achat viagra nitrates viagra can deadly combination Recession quest ce qui peut remplacer le viagra review am astonishingly forgetful. Some things said caffeine was fine to consume (in drinks, food, etc) while on the med, others said caffeine decreased the effects of the med. Features of this disorder include dysphonia, dysarthria, and loss of pain and temperature over the ipsilateral face and contralateral body. Jeg vil også erklære, at du forlader soap ud. If you feel very bored when waiting for something or someone (a bus, your friend, your kids), distract yourself with a book, magazine, or crossword puzzle. The celexa is longer acting and must build in the system over time in order to work for anxiety. Medscape is the leading online destination for healthcare professionals seeking clinical information. Paxil over time increased my appetite but i think that is because les femmes peuvent prendre du viagra made me tired and lethargic, they did not increase appetite, in fact in the first few months they curbed it right down.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0136742 A1 Mickle Et Al
    US 20110136742A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0136742 A1 Mickle et al. (43) Pub. Date: Jun. 9, 2011 (54) ANTIDEPRESSANT PRODRUGS A 6LX 3/5.375 (2006.01) A 6LX 3/553 (2006.01) (76) Inventors: Travis Mickle, Coralville, IA (US); A6II 3/42 (2006.01) Wendy Hirschelman Severs, A6II 3/44 (2006.01) Blacksburg, VA (US) A6II 3/42 (2006.01) A6II 3/405 (2006.01) (21) Appl. No.: 12/280,190 A63L/36 (2006.01) A63/4985 (2006.01) (22) PCT Fled: Feb. 22, 2007 A6II 3/4409 (2006.01) A6II 3/554 (2006.01) A6II 3/405 (2006.01) S371 (c)(1), A6IP 25/24 (2006.01) (2), (4) Date: Sep. 14, 2010 A6IP 25/22 (2006.01) Related U.S. Application Data A6IP 25/18 (2006.01) (52) U.S. Cl. ........ 514/17.6: 514/564: 514/321; 514/217; (60) Provisional application No. 60/776,216, filed on Feb. 514/237.8: 514/211.13: 514/378: 514/354; 24, 2006. 514/376; 514/.424; 514/239.2: 514/.466; 514/250; 514/423: 514/419 Publication Classification (57) ABSTRACT (51) Int. Cl. A6 IK 38/06 (2006.01) The invention provides antidepressant prodrugs comprising A6 IK 38/05 (2006.01) an antidepressant conjugated to one or more amino acids. The A 6LX 3L/95 (2006.01) invention also relates to pharmaceutical compositions com A6 IK 3L/4525 (2006.01) prising an antidepressant prodrug, and to methods of prepar A6 IK3I/55 (2006.01) ing and using the same.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 Dilisa Et Al
    US 2015 0011643A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 DiLisa et al. (43) Pub. Date: Jan. 8, 2015 (54) TREATMENT OF HEART FAILURE AND (60) Provisional application No. 61/038,230, filed on Mar. ASSOCATED CONDITIONS BY 20, 2008, provisional application No. 61/155,704, ADMINISTRATION OF MONOAMINE filed on Feb. 26, 2009. OXIDASE INHIBITORS (71) Applicants:Nazareno Paolocci, Baltimore, MD Publication Classification (US); Univeristy of Padua, Padova (IT) (51) Int. Cl. (72) Inventors: Fabio DiLisa, Padova (IT): Ning Feng, A63L/38 (2006.01) Baltimore, MD (US); Nina Kaludercic, (52) U.S. Cl. Baltimore, MD (US); Nazareno CPC ..... ... A61 K31/138 (2013.01) Paolocci, Baltimore, MD (US) USPC .......................................................... S14/651 (21) Appl. No.: 14/332,234 (22) Filed: Jul. 15, 2014 (57) ABSTRACT Related U.S. Application Data Administration of monoamine oxidase inhibitors is useful in (63) Continuation of application No. 12/407,739, filed on the prevention and treatment of heart failure and incipient Mar. 19, 2009, now abandoned. heart failure. Patent Application Publication Jan. 8, 2015 Sheet 1 of 2 US 201S/0011643 A1 Figure 1 Sial 8. Sws-L) Cleaved Š Caspase-3 ) Figure . Prevention of caspase-3 productief) fron cardiomyocytes Lapoi) reatment with clorgyi Be. Patent Application Publication Jan. 8, 2015 Sheet 2 of 2 US 201S/0011643 A1 Figure 2 8:38:8 ::::::::8: US 2015/0011643 A1 Jan. 8, 2015 TREATMENT OF HEART FAILURE AND in the art is a variety of MAO inhibitors and their pharmaceu ASSOCATED CONDITIONS BY tically acceptable compositions for administration, in accor ADMINISTRATION OF MONOAMINE dance with the present invention, to mammals including, but OXIDASE INHIBITORS not limited to, humans.
    [Show full text]
  • Novel Monoamine Oxidase Inhibitors, 3-(2-Aminoethoxy)-1,2- Benzisoxazole Derivatives, and Their Differential Reversibility
    Jpn. J. Pharmacol. 88, 174 – 182 (2002) Novel Monoamine Oxidase Inhibitors, 3-(2-Aminoethoxy)-1,2- benzisoxazole Derivatives, and Their Differential Reversibility Kenji Yoshimi1,*, Masao Kozuka1, Jyunichi Sakai1, Tomoko Iizawa1, Yuki Shimizu1, Isao Kaneko1, Kouichi Kojima2 and Nobuyoshi Iwata3 1Neuroscience and Immunology Research Laboratories, Sankyo Co., Ltd., 2-58, Hiromachi 1-chome, Shinagawa-ku, Tokyo 140-8710, Japan 2Institute of Science and Technology, Inc., 10-2, Kitashinagawa 3-chome, Shinagawa-ku, Tokyo 140-0001, Japan 3Science Information Co., Ltd., 2-58, Hiromachi 1-chome, Shinagawa-ku, Tokyo 140-8710, Japan Received August 3, 2001 Accepted November 19, 2001 ABSTRACT—Although possible usefulness of non-selective monoamine oxidase (MAO) inhibitors for Parkinson’s disease therapy has been suggested in the literature, MAO inhibitors whose inhibition is reversible and have dual action to both MAO-A and -B subtypes is not available yet. Subtype selectivity and reversibility of a series of novel MAO inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, were studied. Several dual MAO inhibitors, which inhibit both MAO-A and -B, were obtained. When admin- istered to mice, their effects were generally reversible. Among the derivatives, RS-1636 and RS-1653 had much longer duration of brain MAO-B inhibition than that of MAO-A. In vitro, the inhibited MAO-A activity by these compounds was partially recovered by buffer change at 4°C, while little MAO-B activity was recovered. Although it is not fully elucidated yet, the reversibility of these inhibitors is probably determined primarily by this dissociation profile. This unique differential reversibility indicates that optimization of the balance of actions can be achieved by differentiating reversibility to each target molecule.
    [Show full text]
  • Hydroxylamines and Hydrazines As Surrogates of Sp3 Carbons in Medicinal Chemistry
    Wayne State University Wayne State University Dissertations January 2018 Hydroxylamines And Hydrazines As Surrogates Of Sp3 Carbons In Medicinal Chemistry Sandeep Dhanju Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Chemistry Commons Recommended Citation Dhanju, Sandeep, "Hydroxylamines And Hydrazines As Surrogates Of Sp3 Carbons In Medicinal Chemistry" (2018). Wayne State University Dissertations. 2156. https://digitalcommons.wayne.edu/oa_dissertations/2156 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. HYDROXYLAMINES AND HYDRAZINES AS SURROGATES OF SP3 CARBONS IN MEDICINAL CHEMISTRY by SANDEEP DHANJU DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2019 MAJOR: CHEMISTRY (Organic) Approved By: Advisor Date DEDICATION I dedicate my PhD work to my parents Sanubhai Shrestha and Punamaya Dhanju, for their endless love and support. ii ACKNOWLEDGEMENTS First and foremost, I would like to express my sincere gratitude to my Ph.D. advisor Prof. David Crich for his incessant support and guidance for my Ph.D. research work during the past five years in his laboratory. I am grateful and fortunate to be one of his graduate students. His encouragement and motivation drove me to the end of this thesis, and I was able to develop an in-depth knowledge and enthusiasm in the areas of organic chemistry and medicinal chemistry. I would like to extend my gratitude to Prof.
    [Show full text]
  • | Hao Wanat Ha Maria Del Mar Man Unit Minit
    |HAO WANAT HA MARIAUS009731026B2 DEL MAR MAN UNIT MINIT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,731 , 026 B2 Su et al. (45 ) Date of Patent: Aug. 15 , 2017 ( 54 ) NEAT LIQUID PHARMACEUTICAL (58 ) Field of Classification Search FORMULATIONS ??? . .. A61K 8 /02 See application file for complete search history . @( 71) Applicant : Massachusetts Institute of Technology , Cambridge, MA (US ) (56 ) References Cited U . S . PATENT DOCUMENTS @( 72 ) Inventors : Erzheng Su , Cambridge, MA (US ) ; Alexander M . Klibanov , Boston , MA 3 , 800 ,038 A 3 / 1974 Rudel ( US ) 5 ,405 ,617 A 4 / 1995 Gowan 7 , 763 ,653 B2 7 / 2010 Pacheco @( 73 ) Assignee : Massachusetts Institute of 2009/ 0004281 Al * 1 / 2009 Nghiem . .. .. .. .. A61K 9 / 0004 Technology , Cambridge , MA (US ) 424 /490 @( * ) Notice : Subject to any disclaimer , the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U . S . C . 154 ( b ) by 0 days . Abbott , et al ., “ Novel solvent properties of choline chloride /urea mixtures " , Chem . Commun . , 1 : 70 - 71 ( 2003 ) . Abbott, et al. , “ Ionic liquid analogues formed from hydrated metal ( 21 ) Appl. No. : 14 / 951, 055 salts ” , Chem . , Eur. J . , 10 : 3769 -74 ( 2004 ) . Bica , et al ., “ Liquid forms of pharmaceutical co -crystals : Exploring (22 ) Filed : Nov . 24 , 2015 the boundaries of salt formation ” , Chem Comm ., 47 ( 8 ) : 2267- 9 ( 2011 ) . (65 ) Prior Publication Data Grodowska , et al. , “ Organic solvents in the pharmaceutical indus US 2016 / 0143848 A1 May 26 , 2016 try ” , Acta Polomine Pharma. , 67 ( 1 ) : 3 - 12 (2010 ) . International Search Report for Corresponding PCT/ US2015 / Related U . S . Application Data 062470 mailed Feb . 3 , 2016 .
    [Show full text]
  • |||||||IIIHIII USOO5502080A United States Patent 19 11 Patent Number: 5,502,080 Hitzig (45) Date of Patent: Mar
    |||||||IIIHIII USOO5502080A United States Patent 19 11 Patent Number: 5,502,080 Hitzig (45) Date of Patent: Mar. 26, 1996 (54) COMBINED USE OF DOPAMINE AND J. of Substance Abuse Treatment, vol. 11, No. 3, pp. SEROTONN AGONSTS IN THE 273-275, Oct. 1994, Letter to the Editor. TREATMENT OF ALLERGIC DESORDERS Maryland Medical Journal, Feb. 1993, Hitzig, "Combined 76 Inventor: Pietr Hitzig, 1319 Blue Mount Rd., dopamaine and Serotonin agonists: A synergistic approach to Monkton, Md. 2111. alcoholism and other addictive behaviors'. 21 Appl. No.: 333,294 Primary Examiner Marianne M. Cintins 22 Filed: Nov. 1, 1994 Assistant Examiner-William R. A. Jarvis (51) int. Cl. ......................................... A6K 3/135 Attorney, Agent, or Firm-Nixon & Vanderhye 52 U.S. Cl. ............................................. 514/654; 514/885 58 Field of Search ............................................... 514/654 57) ABSTRACT 56) References Cited Allergic conditions are treated and allergic symptoms miti U.S. PATENT DOCUMENTS gated or resolved by the administration of a dopamine 4,255,439 3/1981 Cooper .................................... 424/273 agonist such as fenfluramine and/or 5-hydroxytriptophan 4,895,845 1/1990 Seed ........................................ 54/252 administered concurrently or in association with a serotonin agonist Such as phentermine. OTHER PUBLICATIONS McMurray et al, Medline Abstract No. 94343376, 1994. Bravo et al, Medline Abstract No. 92309257, 1992. Riskind et al, Medline Abstract No. 91315169, 1991. 23 Claims, No Drawings 5,502,080 1. 2 COMBINED USE OF DOPAMINE AND A wider variety of serotonin agonists and dopamine SEROTONN AGONSTS IN THE agonist may be considered for use in the therapeutic meth TREATMENT OF ALLERGIC DISORDERS ods and pharmaceutical compositions of the invention.
    [Show full text]
  • X-Ray Microscope Röntgenstrahlmikroskop Microscope À Rayons X
    (19) TZZ ___T (11) EP 2 511 844 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G06F 21/00 (2013.01) G21K 7/00 (2006.01) 12.08.2015 Bulletin 2015/33 (21) Application number: 12164870.3 (22) Date of filing: 10.10.2007 (54) X-ray microscope Röntgenstrahlmikroskop Microscope à rayons X (84) Designated Contracting States: • Stewart, Jeffrey, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Harris, Michael, N. SI SK TR Los Alamos, NM 87544 (US) • Burrell, Anthony, K. (30) Priority: 10.10.2006 US 850594 P Los Alamos, NM 87544 (US) (43) Date of publication of application: (74) Representative: Lorente Berges, Ana 17.10.2012 Bulletin 2012/42 A2 Estudio Legal C/ Hermosilla Nº 59, bajo izq (62) Document number(s) of the earlier application(s) in 28001 Madrid (ES) accordance with Art. 76 EPC: 07874491.9 / 2 084 519 (56) References cited: WO-A1-97/25614 US-A1- 2003 023 562 (73) Proprietor: XRpro Sciences, Inc. US-A1- 2004 128 518 US-A1- 2004 235 059 Los Alamos, NM 87544 (US) US-A1- 2005 015 596 (72) Inventors: • POTTS PHILIP J ET AL: "Atomic spectrometry • Birnbaum, Eva, R. update__X-ray fluorescence spectrometry", Los Alamos, NM 87544 (US) JOURNAL OF ANALYTICAL ATOMIC • Koppisch, Andrew, T. SPECTROMETRY, ROYAL SOCIETY OF Los Alamos, NM 87544 (US) CHEMISTRY, vol. 21, no.
    [Show full text]
  • WO 2016/064997 Al 28 April 2016 (28.04.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/064997 Al 28 April 2016 (28.04.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61P 25/00 (2006.01) A61K 45/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/566 (2006.01) A61P 37/06 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61K 31/57 (2006.01) A61P 25/24 (2006.01) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (21) International Application Number: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, PCT/US20 15/056649 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 2 1 October 2015 (21 .10.201 5) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/067,264 22 October 20 14 (22.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]